Literature DB >> 17184174

Deferoxamine lowers tissue damage after 80% exchange transfusion with polymerized hemoglobin.

Pedro Cabrales1, Amy G Tsai, Marcos Intaglietta.   

Abstract

Hemoglobin (Hb) solutions have been proposed as potential substitutes for erythrocytes to maintain oxygen-carrying capacity in situations in which blood is not available. This study investigated systemic and microvascular hemodynamics as well as tissue oxygenation and viability after an 80% exchange transfusion with an oxygen-carrying blood substitute based on polymerized bovine hemoglobin (PBH). Studies were carried in unanesthetized hamsters prepared with a window-chamber model for microcirculation evaluation. Heme iron-mediated injury to the tissue was analyzed by using deferoxamine (an iron chelator), which reduces free iron toxicity. Exchange transfusion led to a significant decrease in hematocrit (Hct) and an increase in plasma Hb, in addition to a significant decrease of arteriolar and venular diameters, flow velocity, and, therefore, microvascular blood flow. Capillary perfusion was severely compromised after exchange, but tissue pO2 increased above baseline, and oxygen extraction was reduced. Apoptotic and necrotic cells increased significantly after the exchange; however, this effect was only partially due to the toxicity of free iron. Iron therapy decreased the microvascular and oxygenation changes but did not fully reverse the adverse effects. Assessment of tissue viability after exchange suggests that chelation treatment in cases of large exchange transfusions with acellular Hb could be potentially beneficial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17184174     DOI: 10.1089/ars.2006.1379

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  8 in total

Review 1.  Examining and mitigating acellular hemoglobin vasoactivity.

Authors:  Pedro Cabrales
Journal:  Antioxid Redox Signal       Date:  2012-10-11       Impact factor: 8.401

Review 2.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

3.  Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration.

Authors:  David C Irwin; Paul W Buehler; Jin Hyen Baek; Kathryn Hassell; Rachelle Nuss; Paul Eigenberger; Christina Lisk; Zoe Loomis; Joanne Maltzahn; Kurt R Stenmark; Eva Nozik-Grayck
Journal:  Free Radic Biol Med       Date:  2015-02-02       Impact factor: 7.376

4.  Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin.

Authors:  Pedro Cabrales; Amy G Tsai; K Ananda; Seetharama A Acharya; Marcos Intaglietta
Journal:  Resuscitation       Date:  2008-07-14       Impact factor: 5.262

5.  Isovolemic exchange transfusion with increasing concentrations of low oxygen affinity hemoglobin solution limits oxygen delivery due to vasoconstriction.

Authors:  Pedro Cabrales; Amy G Tsai; Marcos Intaglietta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-03       Impact factor: 4.733

6.  Balance between vasoconstriction and enhanced oxygen delivery.

Authors:  Pedro Cabrales; Amy G Tsai; Marcos Intaglietta
Journal:  Transfusion       Date:  2008-07-09       Impact factor: 3.157

7.  Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock.

Authors:  Chad Brouse; Daniel Ortiz; Yan Su; Bryan Oronsky; Jan Scicinski; Pedro Cabrales
Journal:  Asian J Transfus Sci       Date:  2015 Jan-Jun

8.  Resuscitation From Hemorrhagic Shock With Fresh and Stored Blood and Polymerized Hemoglobin.

Authors:  Alexander T Williams; Alfredo Lucas; Cynthia R Muller; Carlos Munoz; Crystal Bolden-Rush; Andre F Palmer; Pedro Cabrales
Journal:  Shock       Date:  2020-10       Impact factor: 3.533

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.